PLEASANTON, CA -- (MARKET WIRE) -- 12/29/2005 -- Lipid Sciences, Inc. (NASDAQ: LIPD) today reported that it has filed an Investigational Device Exemption (IDE) application with the Center for Devices and Radiological Health of the Food and Drug Administration (FDA). The FDA will be evaluating the completeness of this submission to determine if and when Lipid Sciences can begin a human clinical trial of the Company’s Plasma Delipidation System-2 (PDS-2).